HighTide Therapeutics today announced that the Company will present at the fifth annual NASH-TAG Conference. The hybrid (in-person/virtual) conference, focused on therapeutic agents for non-alcoholic steatohepatitis (NASH) and liver fibrosis, is taking place March 11-13, 2021 in Park City, Utah. HighTide will present data from a Phase 2 clinical trial of HTD1801 in patients with NASH and Type II Diabetes (T2DM).

Additionally, Dr. Adrian Di Bisceglie, Chief Medical Officer of HighTide, will moderate a session on clinical trial results.

The NASH-TAG conference’s primary objective is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with NASH. The conference brings together clinicians, academia, and the pharmaceutical industry to discuss identification of the appropriate patient populations, trial designs, and therapeutic endpoints, as well as the potential benefits these agents can have on patients with NASH.

For any enquiries, please kindly contact:

pr@hightidetx.com